Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
Date:6/3/2008

Dr. Irene Ghobrial of the Dana-Farber Cancer Institute presents phase 2 results demonstrating the single agent clinical activity of perifosine in

patients with relapsed / refractory Waldenstroms Macroglobulinemia

NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) today announced that phase 2 results of perifosine (KRX-0401) in patients with relapsed/refractory Waldenstroms macroglobulinemia (WM) was presented at the 44th Annual Meeting of the American Society of Clinical Oncology. In a poster presentation held earlier today, Dr. Irene Ghobrial, Instructor of Medicine at the Dana-Farber Cancer Institute (DFCI) in Boston, MA, discussed the phase 2 results on the single agent clinical activity of perifosine in patients with both relapsed and/or refractory Waldenstroms macroglobulinemia. The presentation was entitled:

Abstract 8546: A PHASE II TRIAL OF THE NOVEL ORAL AKT INHIBITOR PERIFOSINE (KRX-0401) IN RELAPSED AND/OR REFRACTORY WALDENSTROMS MACROGLOBULINEMIA (WM).

Thirty-seven patients (median age 65 yrs) with advanced WM (76% had at least two prior treatments) were enrolled, with most patients (>75%) previously treated with at least one course of therapy on rituximab. All patients were scheduled to receive 150 mg of perifosine daily in a 28 day cycle for at least 6 cycles. Toxicities were generally well managed and tolerated with Grade 1 & 2 GI related toxicities occurring in 30% of the patients. Thirty-six patients were evaluable for response, assessed by criteria established at the second consensus panel for WM, with results as follows:

Response N Median Duration of Therapy(wks)

Partial Response 2(5%)
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
2. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
3. Keryx Biopharmaceuticals, Inc. Announces Phase 1 and Phase 2 Data on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Multiple Myeloma at 49th Annual Meeting of American Society of Hematology
4. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
5. Keryx Biopharmaceuticals Announces that the SUN-MICRO Phase 3 Clinical Trial Failed to Meet its Primary Efficacy Endpoint
6. Keryx Biopharmaceuticals Announces Termination of SUN-MACRO Phase 4 Trial
7. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
8. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
9. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Aug. 27, 2015 NorthStar Anesthesia , one ... it has been selected by Mercy, based in ... four of their hospitals:  Mercy St. Vincent  Medical Center and ... , Mercy St. Charles  Hospital in Oregon ... Tiffin . "As we looked to ...
(Date:8/27/2015)... TORONTO , Aug. 27, 2015 /PRNewswire/ ... announced the issuance of a white paper on the ... spray product.  The white paper was presented to the ... by Dr. James H. Anderson, Jr. , MD, ... be viewed online on the Generex website. ...
(Date:8/27/2015)...  BioElectronics Corporation (OTC Pink: BIEL), the maker of ... featuring the use of ActiPatch®, its novel musculoskeletal pain ... Congress of the European Pain Federation EFIC®, ... The Company will also be exhibiting at the Congress ... , department clinical and experimental rheumatology from the University ...
Breaking Medicine Technology:Four Mercy Hospitals in Northwest Ohio Select NorthStar Anesthesia 2Generex Announces Issuance of Buccal Insulin White Paper 2Generex Announces Issuance of Buccal Insulin White Paper 3Generex Announces Issuance of Buccal Insulin White Paper 4BioElectronics Selected to Present its Pain Research and Devices at the European Pain Federation Conference 2
... NEW YORK, March 14, 2011 Reportlinker.com announces ... in its catalogue: Insulin Lispro ... http://www.reportlinker.com/p0447411/Insulin-Lispro----Comprehensive-patent-search.html Eliminate unnecessary risk with ... Pipeline Developer is a regularly updated, professional ...
... Tristan Associates, a Harrisburg-based radiology practice operating four ... passing on February 28th of their founder, Theodore Atherton ... "Our physicians and staff are all deeply saddened ... colleague, and friend," said Paul DeLoia, Chief Executive Officer. ...
Cached Medicine Technology:Reportlinker Adds Insulin Lispro - Comprehensive Patent Search 2Reportlinker Adds Insulin Lispro - Comprehensive Patent Search 3Reportlinker Adds Insulin Lispro - Comprehensive Patent Search 4In Memoriam: Theodore Atherton (Ted) Tristan, M.D. 2
(Date:8/28/2015)... Beach, FL. (PRWEB) , ... August 28, 2015 ... ... problems for businesses nationwide. Addictions specialist, Dr. James Strawbridge, gives a new approach ... believes that it should begin with the employer and employees getting together for ...
(Date:8/28/2015)... , ... August 28, 2015 , ... ... patient loyalty at a low cost. Personalized with practice contact information and logos, ... patients. Dental offices can also incorporate Calendars into seasonal mailings, thank you and ...
(Date:8/28/2015)... ... August 28, 2015 , ... Healthpointe clinics ... to go deep sea diving. The act of recreational diving exposes the ... these reasons, it is vital that all recreational and professional divers undergo regular ...
(Date:8/28/2015)... ... 28, 2015 , ... Popular review site Top5MillionaireDatingSites.com recently published ... . According to the listings, MillionaireMatch.com bags the top spot while ... spokesperson of Top5MillionaireDatingSites.com said, “This website has been designed to assist ...
(Date:8/28/2015)... ... August 28, 2015 , ... Inc. magazine today ranked PREVENT Life Safety ... the nation’s fastest-growing private companies. The list was unveiled online at Inc.com and is ... the last three years, PREVENT ranks higher on the list than any other company ...
Breaking Medicine News(10 mins):Health News:SmartPractice® Introduces 2016 Calendars for Dental Practice Giveaways 2Health News:Healthpointe Now Offering Scuba Physicals 2Health News:Top5MillionaireDatingSites.com Publishes Its First List of Reviews of the Best Millionaire Dating Sites 2Health News:PREVENT Life Safety Ranks No. 3660 on the 2015 Inc. 5000 With Three-Year Sales Growth of 85% 2
... the gold standard for detecting colon cancer. But many patients ... invasive test.// Recently, a fecal occult blood stool test has ... stool. However, the test misses a majority of cancers. The ... say the results are encouraging. ,“A simple, non-invasive test ...
... unknown origin are the eighth leading type of cancers. ... Profiling // may now help identify where tumors first ... about 86-percent accurate in determining a tumor’s origin. ... tumor type. Giving the wrong treatment may slow recovery ...
... change in body position may increase an individual’s chances of ... recent study . ,The research is based on a ... or a transient ischemic attack (TIA), also known as a ... common, occur when blood flow to the brain is reduced. ...
... treatment with the oral drug bosentan (Tracleer) has led ... arterial hypertension ( PAH) // . ,PAH is ... is believed to cause the overproduction of endothelin, which ... obstructed. This chronic obstruction leads to PAH, a condition ...
... shows a diet rich in omega-3 and omega-6 fatty acids may ... Researchers say they studied mice to determine the effects of a ... animals were divided into four groups. The first received a diet ... a diet rich in omega-6 fatty acids along with the drug ...
... According to latest research patients who were treated for ... of vitamin B12 in their blood.// An increasing amount ... B and depression, but the specifics have not been ... relationship of vitamin B12 and the treatment of depression. ...
Cached Medicine News:
Inquire...
The model 55D Rocking Shaker provides the same Reliable quality as the 55S, but double the value. The 55D gives you an additional platform with a height of 3.25 in....
Multi-Tier Shaker...
... shake up to 16 of AutoGen's tube units ... This new system is most appropriate for bacterial ... digestion. Now you can further simplify your ... our AutoIncubator 96 and then placing our 6-hole ...
Medicine Products: